Richard Horowitz is a physician specializing in the diagnosis and treatment of Lyme disease, tick-borne coinfections, and chronic illness. His published research primarily focuses on treatment protocols for chronic Lyme disease and post-treatment Lyme disease syndrome, particularly evaluated through dapsone combination therapy regimens and the Multiple Systemic Infectious Disease Syndrome (MSIDS) model. Additionally, his work includes studies on diagnostic assays for babesiosis and clinical reports on therapies for COVID-19.
47 claims checked on air: 5 context 1 contradicted 8 overstated 19 supported 14 unverified
"Now, there are 18 to 19 different subspecies of Bartonella." (said at 0:08:31)
No published record matching the claim that there are 18 to 19 different subspecies of Bartonella was located; this does not prove the claim false.
"And a lot of these long COVID patients who come in with VEGF, with vascular endothelial growth factor, it's not from spike proteins that are actually inflaming the endovascular area, it's basically Bartonella." (said at 0:08:55)
No published record matching the claim that Bartonella infection is the primary cause of vascular endothelial growth factor (VEGF) elevation in long COVID patients was located; this does not prove the claim false. Published literature demonstrates that Bartonella species produce factors (such as the autotransporter BafA) that activate VEGF receptors and stimulate angiogenesis (e.g., PMID 32678094), and elevated VEGF-A expression has been documented in cohorts of patients with long COVID (e.g., PMID 41074076). Additionally, isolated case reports note that Bartonella infections can clinically mimic or coincide with long COVID symptoms (PMID 38472519). However, no clinical or epidemiological study has demonstrated that elevated VEGF in long COVID cohorts is attributable to underlying Bartonella infection.
"BafA interacts with vascular endothelial growth factor (VEGF) receptor-2 and activates the downstream signaling pathway, suggesting that BafA functions as a VEGF analog." (abstract, passage verified)pubmedfull study (doi)
"This case study illustrates how investigating long COVID uncovered an underlying bartonellosis through clinical metagenomics. Following mild COVID-19, a 26-year-old woman experienced persistent symptoms during 5 months, including axillary adenopathy." (abstract, passage verified)pubmedfull study (doi)
"Findings revealed VEGFA overexpression in long COVID patients (effect size 0.322, SE = 0.098, p = 0.0013), along with sex-specific expression patterns and the influence of sex-hormonal status in females, with significant overexpression of circulating VEGFA levels specifically in postmenopausal women" (abstract, results, passage verified)pubmedfull study (doi)
"Lyme patients have migratory joint pain, migratory muscle pain, and migratory nerve pain: tingling, numbness, burning, stabbing, vibration. The hallmark of Lyme is migratory pain." (said at 0:09:45)
While early disseminated Lyme borreliosis can cause transient migratory musculoskeletal symptoms (such as migratory arthralgias and myalgias) and neuroborreliosis can produce radicular neuropathic pain, asserting that 'migratory pain' across joints, muscles, and nerves is the defining hallmark of Lyme disease is overstated. Clinically, the primary pathognomonic hallmark of early Lyme disease is the erythema migrans skin lesion. When musculoskeletal manifestations develop later in the disease, they classically manifest as intermittent or persistent mono- or oligoarthritis predominantly involving large joints (most commonly the knee), rather than generalized migratory polyarticular pain.
"In Lyme disease, arthritis typically emerges as a late manifestation, usually occurring six months after the onset of erythema migrans. The predominant presentation involves mono- or oligoarthritis of large joints, with a chronic or remitting-recurrent course." (abstract, passage verified)pubmedfull study (doi)
"The C6 ELISA checks for three strains: Borrelia burgdorferi, afzelii, garinii from Europe." (said at 0:10:54)
The C6 ELISA utilizes a synthetic 26-mer peptide corresponding to invariable region 6 (IR6) of the VlsE surface lipoprotein. This region is highly conserved across the three main pathogenic genospecies of the Borrelia burgdorferi sensu lato complex responsible for Lyme disease in North America and Europe: Borrelia burgdorferi sensu stricto, Borrelia afzelii, and Borrelia garinii. Consequently, the C6 ELISA detects antibody responses induced by all three species.
"Lyme disease is caused by genetically divergent spirochetes, including 3 pathogenic genospecies: Borrelia burgdorferi sensu stricto, B. garinii, and B. afzelii. Serodiagnosis is complicated by this genetic diversity. A synthetic peptide (C(6)), based on the 26-mer invariable region (IR(6)) of the variable surface antigen of B. burgdorferi (VlsE), was used as ELISA antigen, to test serum samples collected from mice experimentally infected with the 3 genospecies and from European patients with Lyme disease. Regardless of the infecting strains, mice produced a strong antibody response to C(6), which indicates that IR(6) is antigenically conserved among the pathogenic genospecies." (abstract, passage verified)pubmedfull study (doi)
"In Europe, Lyme borreliosis is caused by at least three species, B. burgdorferi sensu stricto, B. afzelii and B. garinii. Thus microbiological diagnosis in European patients must consider the heterogeneity of Lyme disease borreliae for development of diagnostic tools such as PCR primers and diagnostic antigens." (abstract, passage verified)pubmedfull study (doi)
"there's a relapsing fever Borrelia. It's like a cousin of Lyme disease. It's also showing up in 25% of these patients." (said at 0:10:54)
No published record matching the claim that hard tick relapsing fever Borrelia (such as Borrelia miyamotoi) is found in 25% of chronically ill Lyme-like patients was located; this does not prove the claim false. Published seroprevalence surveys in cohorts with chronic, complex, or Lyme-like illnesses report variable and distinct seropositivity rates (for example, approximately 10% standard Borrelia seropositivity in Canadian chronic illness cohorts), but do not corroborate a 25% detection rate for relapsing fever Borrelia species.
"you get Lyme and Bartonella, which causes immune deficiency. So it destroys your B cells from the bone marrow that make antibodies. 20% of my patients come in with common variable immune deficiency, 85% subclass deficiency." (said at 0:11:39)
No published record matching the claim that Lyme disease and Bartonella infection destroy bone marrow B cells to cause common variable immunodeficiency in 20% of patients or IgG subclass deficiency in 85% of patients was located; this does not prove the claim false.
"and they get mold toxins with gliotoxins on top of it, which are immunosuppressive." (said at 0:12:28)
Gliotoxin, a sulfur-containing epipolythiodioxopiperazine (ETP) secondary metabolite produced by fungal species such as Aspergillus fumigatus and Trichoderma, is well-established in the toxicological and microbiological literature as a potent immunosuppressive agent. It impairs host immunity through multiple mechanisms, including inhibition of NF-κB signaling, inhibition of macrophage activation and phagocytosis, generation of reactive oxygen species, and induction of apoptosis in host immune cells.
"Furthermore, GT is long known as an immunosuppressive agent and also reported to have anti-tumour properties. However, recent publications suggest that GT is a virulence determinant of the human pathogen Aspergillus fumigatus." (abstract, passage verified)pubmedfull study (doi)
"Among the different secondary metabolites produced by Aspergillus spp. Gliotoxin (GT) is the best known and better characterized virulence factor. It is able to generate reactive oxygen species (ROS) due to the disulfide bridge present in its structure. It also presents immunosuppressive activity related with its ability to kill mammalian cells and/or inactivate critical immune signaling pathways like NFkB." (abstract, passage verified)pubmedfull study (doi)
"Gliotoxins show cytotoxic effects via the suppression the function of macrophage immune function, inflammation, antiangiogenesis, DNA damage by ROS production, peroxide damage by the inhibition of various enzymes, and apoptosis through different signal pathways." (abstract, passage verified)pubmedfull study (doi)
"The Lyme is causing anti-dopaminergic antibodies, anti-thyroid antibodies, anti-cardiolipin antibodies, anti-myelin antibodies. It's causing this auto—so people come in with these autoimmune illnesses, but it's Lyme causing molecular mimicry. Your immune system is attacking the bug, right, the flagella, and it's causing these autoantibodies." (said at 0:17:53)
While research has demonstrated that immune responses to Borrelia burgdorferi flagellin can cross-react with human axonal proteins (such as heat shock protein 60, HSP60) in in vitro and preclinical models, the claim that flagellar molecular mimicry causes a broad array of specific autoantibodies—including anti-dopaminergic, anti-thyroid, anti-cardiolipin, and anti-myelin antibodies—significantly overstates the evidence. Some anti-neuronal antibodies (such as anti-D1 dopamine receptor antibodies) have been preliminarily observed in small subsets of patients with recurrent Lyme disease, but a causative mechanism linking flagella-targeted molecular mimicry to these diverse autoimmune targets in clinical disease is unestablished.
"EM + prior LD cases had higher antibody titers than controls for anti-lysoganglioside GM1 (p = 0.002), anti-tubulin (p = 0.03), and anti-D1R (p = 0.02), as well as higher expression in the functional antibody-mediated CaMKII Assay (p = 0.03). The EM cases with no prior history showed no significant differences on any measures. The PTLS cases demonstrated significantly higher titers (p = 0.01) than controls on anti-lysoganglioside GM1, but not for the other measures." (abstract, results)pubmedfull study (doi)
"A monoclonal antibody (H9724), specific for the 41-kDa flagellar protein of the Lyme disease pathogen Borrelia burgdorferi, cross-reacts with human axons and detects one major protein in human neuroblastoma cell extracts. The homologous cross-reacting protein has now been isolated from calf adrenal and identified as chaperonin-HSP60 by N-terminal sequencing." (abstract, passage verified)pubmedfull study (doi)
"Previous work has demonstrated that the organism's flagellin cross-reacts with a component of human peripheral nerve axon, heat shock protein 60. The cross-reacting epitope is identified by a single anti-B. burgdorferi flagellin monoclonal antibody, H9724." (abstract, results, passage verified)pubmedfull study (doi)
"if you give sulforaphane glucosinolate, broccoli seed extract, to the autistic population, they did it at Johns Hopkins, a third of these kids, their brains—and the same thing with the Alzheimer's." (said at 0:22:15)
A landmark pilot randomized, placebo-controlled trial conducted by researchers at Johns Hopkins University School of Medicine and Massachusetts General Hospital evaluated sulforaphane derived from broccoli sprout extract in 44 young males (aged 13–27) with autism spectrum disorder (ASD). In that trial, sulforaphane treatment resulted in a 34% average reduction (improvement) in Aberrant Behavior Checklist (ABC) scores compared to placebo, which is frequently misquoted or conflated as improving one-third of participants. A subsequent randomized trial in children aged 3–12 found small, non-statistically significant improvements on the primary clinician-rated outcome measure, though secondary caregiver ABC ratings did show improvement.
"After 18 wk, participants receiving placebo experienced minimal change (<3.3%), whereas those receiving sulforaphane showed substantial declines (improvement of behavior): 34% for ABC (P < 0.001, comparing treatments) and 17% for SRS scores (P = 0.017)." (abstract, results, passage verified)pubmedfull study (doi)
"Treatment effects on the primary outcome measure, the Ohio Autism Clinical Impressions Scale (OACIS), in the general level of autism were not significant between SF and PL groups at 7 and 15 weeks... Caregiver ratings on secondary outcome measures improved significantly on the Aberrant Behavior Checklist (ABC) at 15 weeks (Cohen's d - 0.96; 95% CI - 1.73, - 0.15), but not on the Social Responsiveness Scale-2 (SRS-2)." (abstract, results)pubmedfull study (doi)
"When we look intracellularly at the red blood cell zinc, the red blood cell copper, the red blood cell magnesium, we're finding up to 20% of our patients are deficient, which means you cannot detoxify properly and deal with inflammation." (said at 0:23:18)
No published record matching the claim that up to 20% of chronically ill patients are deficient in intracellular red blood cell zinc, copper, and magnesium was located; this does not prove the claim false.
"I wrote the first article in the world literature in COVID-19 in April 2020 on glutathione and how it helps with COVID." (said at 0:24:10)
Richard I. Horowitz and colleagues published a two-patient case report titled 'Efficacy of glutathione therapy in relieving dyspnea associated with COVID-19 pneumonia: A report of 2 cases' in Respiratory Medicine Case Reports in April 2020. This was the first published article in the medical literature evaluating clinical treatment with oral and intravenous glutathione in patients with COVID-19 pneumonia. However, because this publication is an uncontrolled case report of only two patients, it provides very low certainty clinical evidence regarding the true therapeutic efficacy of glutathione in COVID-19.
"We evaluated the effects of using high dose oral and/or IV glutathione in the treatment of 2 patients with dyspnea secondary to COVID-19 pneumonia. Two patients living in New York City (NYC) with a history of Lyme and tick-borne co-infections experienced a cough and dyspnea and demonstrated radiological findings consistent with novel coronavirus pneumonia (NCP). A trial of 2 g of PO or IV glutathione was used in both patients and improved their dyspnea within 1 h of use." (abstract, results, passage verified)pubmedfull study (doi)
"I didn't know at the time that the virus needs to lower glutathione to replicate." (said at 0:24:38)
In vitro mechanistic studies indicate that SARS-CoV-2 infection promotes a pro-oxidant intracellular environment by depleting reduced glutathione (GSH), which facilitates viral replication. In cell culture models (such as Vero E6, Calu-3, and A549 cells), viral infection markedly reduces cellular GSH, while restoring intracellular glutathione balance or administering thiol donors significantly suppresses viral replication and inflammation. Furthermore, molecular studies demonstrate that glutathionylation of the SARS-CoV-2 main protease (Mpro) inhibits its dimerization and enzymatic activity, showing that higher glutathione levels directly impair replication mechanisms. However, because this evidence is derived exclusively from in vitro and molecular models, the clinical certainty is very low.
"Viral infections sustain their replication cycle promoting a pro-oxidant environment in the host cell. In this context, specific alterations of the levels and homeostatic function of the tripeptide glutathione have been reported to play a causal role in the pro-oxidant and cytopathic effects (CPE) of the virus. In this study, these aspects were investigated for the first time in SARS-CoV2-infected Vero E6 cells, a reliable and well-characterized in vitro model of this infection. SARS-CoV2 markedly decreased the levels of cellular thiols, essentially lowering the reduced form of glutathione (GSH)." (abstract, results, passage verified)pubmedfull study (doi)
"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent for coronavirus disease 2019 (COVID-19), encodes two proteases required for replication... We show M pro is susceptible to glutathionylation, leading to inhibition of dimerization and activity." (abstract, results)pubmedfull study (doi)
"It also alters the host antioxidant response, causing oxidative stress that supports viral replication and cytokine overproduction. This study investigated key pathogenic effectors in Calu-3 and A549-ACE2/TMPRSS2 cells infected with SARS-CoV-2 variants, focusing on replication kinetics, cellular redox state, and inflammatory cytokine profile. A dramatic redox alteration in terms of glutathione (GSH) and Cysteine (Cys) was observed at 48 h p.i., along with a strong pro-inflammatory cytokine response" (abstract, results, passage verified)pubmedfull study (doi)
"And I also didn't know that NAC was blocking von Willebrand factor, so they weren't getting microclots and dying from it." (said at 0:24:39)
Preclinical and translational studies demonstrate that N-acetylcysteine (NAC) cleaves disulfide bonds in ultra-large von Willebrand factor (VWF) multimers, thereby reducing multimer size, disrupting VWF-mediated platelet aggregation, and inhibiting or dissolving microvascular thrombi.
"Instead, we propose using N-acetyl cysteine (NAC) to act against the protein VWF (von Willebrand factor), and not platelets, to prevent arterial thrombi from forming." (abstract, background, passage verified)pubmedfull study (doi)
"NAC improves renal MBF, possibly by reducing VWF multimer size and reducing microthrombus burden." (abstract, conclusions, passage verified)pubmedfull study (doi)
"N-acetylcysteine (NAC) has been explored as an adjunctive therapy because of its ability to reduce disulfide bonds within von Willebrand factor multimers." (abstract, introduction, passage verified)pubmedfull study (doi)
"low-dose naltrexone, one of my favorites also for blocking the third pathway, NLRP3 inflammasomes" (said at 0:25:00)
Low-dose naltrexone (and its stereoisomer (+)-naltrexone) attenuates neuroinflammation primarily by antagonizing Toll-like receptors 2 and 4 (TLR2/TLR4) on microglia, which secondarily reduces downstream inflammatory signaling, including the expression of NLRP3 and interleukin-1β (IL-1β). Describing naltrexone as a direct blocker of the NLRP3 inflammasome pathway conflates upstream TLR antagonism with direct NLRP3 inhibition (such as by specific inhibitors like MCC950). Furthermore, support for this mechanism derives from preclinical rodent models rather than human clinical trials.
"This was associated with increased mRNA for hippocampal interleukin-1β (IL-1β), TLR2, TLR4, NLRP3, and IL-17 and elevated expression of the microglial marker Iba1 in CA1 and DG regions of the hippocampus, confirming the neuroinflammation observed in higher-dose EAE models. Importantly, (+)-NTX completely prevented the EAE-induced memory impairments and robustly attenuated the associated proinflammatory effects." (abstract, results, passage verified)pubmedfull study (doi)
"Exploring further mechanisms, we demonstrated that both spinal NOD-like receptor protein 3 (NLRP3) and interleukin-17 (IL-17) are necessary for EAE-induced pain, as intrathecal injections of NLRP3 antagonist MCC950 and IL-17 neutralizing antibody both acutely reversed EAE-induced pain." (abstract, results, passage verified)pubmedfull study (doi)
"when you don't sleep, IL-6, interleukin-6, is high, it's driving inflammation." (said at 0:26:32)
Published meta-analyses support the claim that sleep loss and sleep disturbances are associated with elevated levels of the pro-inflammatory cytokine interleukin-6 (IL-6). In observational studies, sleep disturbance is significantly associated with higher systemic IL-6 levels. In experimental human trials, sustained partial sleep deprivation (e.g., restriction to approximately 4.5 hours per night for three or more consecutive nights) significantly increases circulating IL-6, although a single acute night of total or partial deprivation may not produce a significant change.
"A total of 72 studies (n > 50,000) were analyzed with assessment of C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor α (TNFα). Sleep disturbance was associated with higher levels of CRP (ES .12; 95% CI = .05-.19) and IL-6 (ES .20; 95% CI = .08-.31)." (abstract, results, passage verified)pubmedfull study (doi)
"Compared to normal sleep, multiple nights of experimental partial sleep deprivation (sleep duration reduced to ~4.30 h for 3+ nights) were associated with a significant increase of interleukin-6 [IL-6, k = 5, d = 0.42, [95% CI = 0.11 to 0.73], p < 0.01] and C-reactive protein [CRP, k = 5, d = 0.76, [95% CI = 0.09 to 1.43], p = 0.03] in blood. A single night of total or partial sleep deprivation was not associated with changes in inflammation." (abstract, results, passage verified)pubmedfull study (doi)
"I recently published an article in the Journal of Alzheimer's Disease Reports... I reversed for the first time ever in the world the most sensitive and specific biomarker for Alzheimer's, p-tau217... when we treated the Lyme disease with the 9 weeks of dapsone combination therapy... completely reversed p-tau217." (said at 0:28:33)
No published record matching the claim of complete reversal of the p-tau217 biomarker following dapsone combination therapy in the Journal of Alzheimer's Disease Reports was located; this does not prove the claim false.
"We're in the middle of an Alzheimer's epidemic where the NIH said that 42% of people over 55 years old are now going to become demented." (said at 0:29:34)
A 2025 prospective cohort study of 15,043 individuals published in Nature Medicine (funded by the NIH) evaluated lifetime dementia risk from age 55 to 95 years while accounting for mortality as a competing risk. The authors found that the lifetime risk of developing dementia after age 55 was 42% (95% CI: 41–43%), closely matching the claim.
"The lifetime risk of dementia after age 55 years was 42% (95% confidence interval: 41-43). Rates were substantially higher in women, Black adults and APOE ε4 carriers, with lifetime risks ranging from approximately 45% to 60% in these populations." (abstract, results, passage verified)pubmedfull study (doi)
"they looked at autopsy studies of Alzheimer's patients and they would find biofilms, amyloid, and phosphorylated tau in the brains." (said at 0:30:05)
Autopsy studies evaluating the microbial hypothesis of Alzheimer's disease have reported finding bacterial biofilm markers co-localizing with classic neuropathological hallmarks, including amyloid-beta and phosphorylated tau (p-Tau). For example, post-mortem immunohistochemical analysis of Alzheimer's disease brain tissue identified Borrelia burgdorferi aggregates positive for the biofilm marker alginate co-localized with amyloid and phospho-tau markers. Amyloid-beta and hyperphosphorylated tau are standard pathological hallmarks of Alzheimer's disease, while evidence for bacterial biofilms in AD brain tissue comes from preliminary, small-sample autopsy studies.
"Positive Borrelia structures were evaluated for co-localization with biofilm and AD markers such as amyloid and phospho-tau (p-Tau) using immunohistochemical methods. The results showed the presence of B. burgdorferi antigen and DNA in patients with AD pathology and among those, one of them was previously diagnosed with Lyme disease. Interestingly, a significant number of Borrelia-positive aggregates with a known biofilm marker, alginate, were found along with the spirochetal structures. Our immunohistochemical data also showed that Borrelia-positive aggregates co-localized with amyloid and phospho-tau markers." (abstract, methods and results, passage verified)pubmedfull study (doi)
"And the drugs that are used for it, lecanemab, they lowered phosphorylated tau by 23% in almost 7 years." (said at 0:30:35)
The claim that lecanemab lowered phosphorylated tau by 23% over nearly 7 years is contradicted by clinical trial evidence. In the primary Phase 3 clinical trial (Clarity AD), lecanemab was evaluated over an 18-month (1.5-year) double-blind period, not 7 years. While lecanemab significantly reduced amyloid markers and slowed clinical decline compared with placebo at 18 months, published clinical trials and long-term pharmacodynamic modeling evaluate outcomes over 18 months to 4 years, making the claimed 7-year timeframe inaccurate.
"We conducted an 18-month, multicenter, double-blind, phase 3 trial involving persons 50 to 90 years of age with early Alzheimer's disease (mild cognitive impairment or mild dementia due to Alzheimer's disease) with evidence of amyloid on positron-emission tomography (PET) or by cerebrospinal fluid testing." (abstract, methods, passage verified)pubmedfull study (doi)
"Simulations were conducted to evaluate the effect of lecanemab (10 mg/kg IV every 2 weeks, LEC10-BW) after 4 years of continuous treatment, discontinuation after 18 months of treatment or transitioning to less frequent dosing at 18, 24, or 30 months." (abstract, methods, passage verified)pubmedfull study (doi)
"I lowered it by 63% in 9 weeks. And that was because it was the infection driving the amyloid and the phosphorylated tau." (said at 0:30:35)
No published record matching the claim that a 9-week dapsone combination protocol reduced phosphorylated tau (p-tau217) levels by 63% in a patient was located; this does not prove the claim false. While published clinical studies and case series on dapsone combination protocols in chronic Lyme disease and post-treatment Lyme disease syndrome exist (e.g., PMID 38792737, PMID 37764145, PMID 35884166, PMID 33105645), none of these published reports document or report data on p-tau217 reductions or tau biomarker changes associated with dapsone therapy.
"There was a trial published uh I think the other day on ketogenic diets. It was a randomized controlled trial for bipolar I and schizophrenia and psychosis showing reversal." (said at 0:31:55)
A randomized controlled trial evaluated an adjunctive ketogenic diet in outpatients with schizophrenia-spectrum and bipolar I disorders (n = 58; 1-month randomized phase vs. diet-as-usual, followed by an optional 4-month extension). The trial found statistically significant improvements in metabolic parameters (such as weight, HbA1c, and insulin resistance), cognitive performance, and psychiatric symptom scores (including depression and positive/negative symptoms). However, the study demonstrated modest-to-moderate symptom reduction and feasibility, not disease "reversal" or cure.
"Participants were randomized to a ketogenic diet (KETO; n = 28) or diet-as-usual (DAU; n = 30) for 1 month. Partway through the trial, a KETO extension was offered to both groups, resulting in a sub-group who completed the diet for 4 months (n = 25)... Clinical symptoms (positive, negative, depression) and cognitive performance improved after 4 months on the KETO (all P-values < .001)... We demonstrate feasibility of administering a KETO in outpatients with schizophrenia and bipolar-1 disorder. Participants showed improvement in metabolic health, cognitive performance, and clinical symptoms." (abstract, methods and results, passage verified)pubmedfull study (doi)
"about 10 years ago, Johns Hopkins researchers found out that Lyme was a specific type of a bacteria called a biofilm persister bacteria, like tuberculosis and leprosy." (said at 0:33:06)
Starting around 2014-2015, researchers at Johns Hopkins Bloomberg School of Public Health (led by Dr. Ying Zhang, who previously studied persister mechanisms in Mycobacterium tuberculosis) published a series of studies showing that Borrelia burgdorferi in stationary phase forms antibiotic-tolerant persister cells and biofilm-like microcolonies in vitro and in animal models. The researchers screened drug libraries to identify agents active against these dormant forms, drawing direct parallels to persistent infection paradigms such as tuberculosis. While persister and biofilm formation represents a phenotypic state rather than a separate taxonomic class of bacteria, and the clinical significance of these forms in human Post-Treatment Lyme Disease Syndrome (PTLDS) remains an active area of investigation based largely on preclinical evidence, the attribution to Johns Hopkins researchers and the timing accurately reflect the published literature.
"Although not a clinical surrogate, insight may be gained by examining stationary-phase in vitro Borrelia burgdorferi persisters that survive treatment with the antibiotics doxycycline and amoxicillin. To identify drug candidates that can eliminate B. burgdorferi persisters more effectively, we screened an Food and Drug Administration (FDA)-approved drug library consisting of 1524 compounds against stationary-phase B. burgdorferi" (abstract, results, passage verified)pubmedfull study (doi)
"Here we isolated the biofilm-like microcolony (MC) and planktonic (spirochetal form and round body) (SP) variant forms from the stationary phase culture of B. burgdorferi and showed that the MC and SP variant forms were not only more tolerant to the current Lyme antibiotics but also caused more severe arthritis in mice than the log phase spirochete form (LOG)." (abstract, results, passage verified)pubmed
"I looked at dapsone, and it was, all right, it gets great penetration into the brain... number two, it blocks NLRP3 inflammasomes in the brain." (said at 0:34:07)
Published literature confirms both components of the claim. Pharmacokinetic studies in humans demonstrate that dapsone crosses the blood-brain barrier and penetrates into cerebrospinal fluid (CSF). Preclinical mechanistic and animal studies show that dapsone acts as an inflammasome competitor and inhibits NLRP3 inflammasome activation and downstream neuroinflammatory signaling (such as IL-1β and IL-18) in the brain.
"The specific targeting of NLRP3 itself or up-/downstream factors of the NLRP3 inflammasome by DDS may be responsible for its observed preventive effects, functioning as a competitor." (abstract, conclusions, passage verified)pubmedfull study (doi)
"This study highlights the therapeutic potential of dapsone in epilepsy, emphasizing the involvement of Nrf2/HO-1 and NLRP3 pathways." (abstract, conclusions, passage verified)pubmedfull study (doi)
"So in a study by Lee et al. with like 3 to 4,000 people over 16 years, he gave them 100 milligrams of dapsone, the rates of Alzheimer's were like this, and the people who didn't take dapsone was six times higher." (said at 0:34:25)
A 2022 study by Lee et al. (PMID 35542045) evaluated Alzheimer's disease (AD) diagnoses in South Korean leprosy patients according to dapsone prescription history. The study reported that leprosy patients not prescribed dapsone had significantly higher rates of AD diagnosis compared to those taking dapsone (with an approximate sixfold difference across cohort comparisons). However, the claim frames this as a clinical trial where the author 'gave them 100 milligrams of dapsone' over 16 years, whereas it was a retrospective observational cohort analysis of health insurance and leprosy registry data. Observational studies in this population are subject to substantial confounding by indication, survivorship, and differential healthcare access, and do not establish a causal preventive effect of dapsone in the general population.
"Our study investigated patients with leprosy and AD. They were treated with dapsone (4,4'-diaminodiphenyl sulfone, DDS) as a neuroinflammasome competitor and cGAS/STING pathway inhibitor. Four groups were defined: Treatment (T) 1: DDS prescribed AD diagnosed, T 2: DDS prescribed AD undiagnosed, T 3 DDS unprescribed AD diagnosed, and T 4: DDS unprescribed AD undiagnosed. Dapsone effects on AD can be clearly distinguished according to dapsone presence or absence. T1:T3 proved that the incidence of AD was significantly reduced by dapsone." (abstract, results, passage verified)pubmedfull study (doi)
"It has antimalarial properties; it hits, not great, but about 25% of the Babesia cases." (said at 0:34:45)
While dapsone has established antimalarial activity (historically used in antifolate combination therapies such as Lapdap and Maloprim), no clinical trials or published evidence establish that dapsone monotherapy or protocols achieve efficacy in approximately 25% of Babesia cases. Standard first-line treatments for human babesiosis remain atovaquone plus azithromycin or clindamycin plus quinine; in observational reports of dapsone combination regimens used for chronic tick-borne illness, Babesia coinfections typically require separate antimalarial regimens.
"Babesia required rotations of multiple anti-malarial drug combinations and herbal therapies, and Bartonella required one or several 6-day HDDCT pulses to achieve clinical remission." (abstract, results, passage verified)pubmedfull study (doi)
"I published my first article 2016 on 100 patients on low-dose dapsone. Fatigue got better, joint pain got better, neuropathy got better, brain fog; headaches was the only thing statistically that didn't improve." (said at 0:34:55)
No published record matching a 2016 study of 100 patients evaluating low-dose dapsone combination therapy for chronic Lyme disease symptoms was located; this does not prove the claim false. Subsequent retrospective observational analyses by the author evaluated cohorts of 200 patients receiving dapsone combination therapy, reporting improvements across several chronic symptom categories.
"if you have Lyme without active Babesia, Bartonella, without mold, this protocol will put about half of the people in remission from nine weeks of antibiotics." (said at 0:35:15)
Published retrospective chart reviews from the clinician's practice report similar figures: in a retrospective series of 40 patients treated with 7–8 weeks of double-dose dapsone combination therapy (DDDCT), 45% (18/40) remained in remission for 1 year or longer. In a subsequent review of 25 patients receiving 8 weeks of DDDCT followed by a 5–7 day high-dose pulse (~9 weeks total), 30.5% (7/23 evaluable) achieved remission at 3–9 months and 13% (3/23) at 1.5 months (~43.5% total). However, presenting these findings as a definitive clinical rule ("will put about half of the people in remission") overstates the evidence, which consists entirely of small, unblinded, uncontrolled retrospective chart reviews and case series from a single practice without randomized controls.
"A retrospective chart review of 37 additional patients undergoing DDD CT therapy (40 patients in total) was also performed, which demonstrated tick-borne symptom improvements in 98% of patients, with 45% remaining in remission for 1 year or longer." (abstract, results, passage verified)pubmedfull study (doi)
"At the completion of treatment, 7/23 (30.5%) who completed 8 weeks of DDDCT followed by a 5-7 day pulse of HDDCT remained in remission for 3-9 months, and 3/23 patients (13%) who recently finished treatment were 1 ½ months in full remission." (abstract, results, passage verified)pubmedfull study (doi)
"So, we found, and I did a study with Eva Sapi from the University of New Haven in culture... every time we added a drug, like when we added doxycycline to dapsone, it lowered the biofilm persisters; we added rifampin to doxy and dapsone, it lowered the biofilm even more. We added Zithromax." (said at 0:35:39)
A 2020 in vitro study co-authored by Richard Horowitz and Eva Sapi evaluated dapsone alone and in combination with doxycycline, rifampin, and azithromycin against Borrelia burgdorferi biofilm forms. The culture study showed that combining dapsone with these intracellular antibiotics significantly decreased biofilm mass, viability, and protective glycosaminoglycan content compared to monotherapies. Because these findings are derived exclusively from in vitro cell culture models, certainty regarding clinical translation to human Lyme disease remains very low.
"Dapsone, alone or in various combinations with doxycycline, rifampin and azithromycin produced a significant reduction in the mass and protective glycosaminoglycan layer and overall viability of B. burgdorferi biofilm forms." (abstract, results, passage verified)pubmedfull study (doi)
"where BMJ Global Health said one out of seven people in the world have now been exposed to Lyme, right?" (said at 0:36:55)
A 2022 systematic review and meta-analysis published in BMJ Global Health (Dong et al., pooling 89 studies comprising 158,287 participants) estimated the global seroprevalence of Borrelia burgdorferi sensu lato at 14.5% (95% CI 12.8% to 16.3%), which corresponds to approximately one in seven individuals having serological evidence of exposure.
"Of 4196 studies, 137 were eligible for full-text screening, and 89 (158 287 individuals) were included in meta-analyses. The reported estimated global Bb seroprevalence was 14.5% (95% CI 12.8% to 16.3%), and the top three regions of Bb seroprevalence were Central Europe (20.7%, 95% CI 13.8% to 28.6%), Eastern Asia (15.9%, 95% CI 6.6% to 28.3%) and Western Europe (13.5%, 95% CI 9.5% to 18.0%)." (abstract, results, passage verified)pubmedfull study (doi)
"And the reason for Plaquenil, by the way, is it alkalizes the intracellular compartment so these antibiotics are more effective, helps with the autoimmune manifestations, um even hits the cystic forms of Lyme" (said at 0:39:14)
The speaker's claims accurately reflect published hypotheses and in vitro findings, though evidence is limited primarily to in vitro models and observational clinical data. Hydroxychloroquine is a weak base (lysosomotropic agent) that concentrates in acidic intracellular compartments (such as endosomes and lysosomes) and elevates their pH toward neutrality. Studies evaluating Lyme disease therapy (e.g., Donta, 2003) noted that macrolide antibiotics lose efficacy at acidic pH, and adding hydroxychloroquine alkalinizes these compartments to enhance antibiotic effectiveness. Additionally, an in vitro study by Brorson et al. (2002) demonstrated that hydroxychloroquine has direct bactericidal activity against cystic forms of Borrelia burgdorferi and disrupts/ruptures cystic structures. However, certainty is low because clinical evidence supporting this regimen comes primarily from uncontrolled observational cohorts and in vitro experiments rather than rigorous randomized controlled trials.
"When the concentration of HCQ was >= MBC, core structures did not develop inside the cysts, and the amount of RNA in these cysts decreased significantly. Spirochetal structures inside the cysts dissolved in the presence of high concentrations of HCQ." (abstract)pubmedfull study (doi)
"As macrolides are less active at a low pH, their poor clinical activity might be due to localization of borrelia to an acidic endosome, and their activity improved by alkalinization of that compartment with hydroxychloroquine." (abstract, passage verified)pubmed
"Tufts, by the way, published one that showed that this combination rifampin/dapsone cures Lyme in the animal model." (said at 0:39:35)
No published record matching the claim that a study from Tufts University demonstrated a combination of rifampin and dapsone cures Lyme disease in an animal model was located; this does not prove the claim false. Published studies on dapsone combinations for Borrelia burgdorferi infection include in vitro evaluation of antibiotic combinations against stationary-phase or biofilm forms (such as PMIDs 32993780 and 28327498) and human case reports, but no study from Tufts University demonstrating cure in an animal model was identified in the published literature.
"Johns Hopkins again, they published that if you do for 6 days in culture rifampin, Zithromax, and methylene blue, it kills Bart." (said at 0:40:15)
A 2020 in vitro study by researchers at the Johns Hopkins Bloomberg School of Public Health (Zheng et al., BMC Microbiology) evaluated drug combinations against stationary phase and biofilm-forming Bartonella henselae. The researchers found that methylene blue and rifampin were the most active single agents and that two-drug combinations containing azithromycin, rifampin, and methylene blue (such as azithromycin/methylene blue and rifampin/methylene blue) completely eradicated biofilm B. henselae after 6 days of exposure in culture. Because these findings are strictly in vitro, clinical efficacy in humans remains unestablished.
"Methylene blue and rifampin were the most active agents against the biofilm B. henselae after 6 days of drug exposure. Antibiotic combinations (azithromycin/ciprofloxacin, azithromycin/methylene blue, rifampin/ciprofloxacin, rifampin/methylene blue) completely eradicated the biofilm B. henselae after treatment for 6 days." (abstract, results, passage verified)pubmedfull study (doi)
"in the blood plasma supply when they're treating for all the red blood cells they're storing. Methylene blue is what's used to kill all the infectious agents that's in our blood supply." (said at 0:40:45)
Methylene blue combined with visible light (such as the Theraflex MB-Plasma system) is a well-established pathogen reduction technology used specifically to treat therapeutic plasma units to inactivate viruses and other infectious pathogens. However, the speaker incorrectly asserts that methylene blue is used to treat stored red blood cells or to clear infectious agents from the whole red blood cell supply; methylene blue pathogen inactivation is specific to plasma (and in some systems platelets), whereas red blood cell concentrates require distinct pathogen reduction technologies (such as amustaline/S-303) because methylene blue causes hemolysis or binding issues when applied directly to red blood cells.
"We have evaluated the efficacy of photodynamic treatment of fresh frozen plasma (FFP) with methylene blue (MB), a decontamination method applied in several European countries." (abstract, background, passage verified)pubmedfull study (doi)
"The technologies to be discussed include solvent detergent and methylene blue treatments--designed to inactivate plasma components and derivatives; psoralens (S-59--amotosalen) designed to pathogen-reduce units of platelets; and two products aimed at red blood cells, S-303 (a Frale--frangible anchor-linker effector compound) and Inactine (a binary ethyleneimine)." (abstract, results, passage verified)pubmedfull study (doi)
"These testosterone shots are shrinking your testicles by 15%, and they're stopping your own hormone production." (said at 0:41:55)
No published record matching the claim that testosterone shots shrink testicles by approximately 15% while halting endogenous hormone production was located in the retrieved records; this does not prove the claim false.
"One-third of the world's population has non-alcoholic steatohepatitis or fatty liver." (said at 0:49:23)
Large systematic reviews and meta-analyses estimate that approximately one-third of the global adult population has non-alcoholic fatty liver disease (NAFLD, now often termed metabolic dysfunction-associated steatotic liver disease or MASLD). A 2022 meta-analysis across 72 studies comprising over 1 million individuals found a worldwide pooled prevalence of 32.4% (95% CI: 29.9%–34.9%), with more recent estimates ranging from 30% to 38%.
"In total, 72 publications with a sample population of 1 030 160 individuals from 17 countries were included in the prevalence analysis... The overall prevalence of NAFLD worldwide was estimated to be 32·4% (95% CI 29·9-34·9)." (abstract, results)pubmedfull study (doi)
"The metabolically-based liver disease, nonalcoholic fatty liver disease (NAFLD), is the most common cause of chronic liver disease currently affecting 38% of the world's adult population." (abstract, background, passage verified)pubmedfull study (doi)
"and dysautonomia shows up in 40 to 50% of our patients at this point." (said at 0:50:20)
While subjective autonomic symptoms and certain hemodynamic abnormalities (such as orthostatic hypotension) are frequently reported in post-treatment and late-stage Lyme disease, the claim that postural orthostatic tachycardia syndrome (POTS) specifically occurs in 40% to 50% of patients overstates published objective findings. A study of 210 patients with post-treatment Lyme disease (PTLD) found that while autonomic symptom scores (COMPASS-31) were elevated, objective orthostatic tachycardia on a 10-minute active stand test was present in only 4.29% (9 of 210) of patients, a rate not significantly different from healthy controls. Other specialized cohort studies of late-stage Lyme disease have found orthostatic hypotension in 53.4% of patients during head-up tilt testing, but reviews note that formal dysautonomia remains an under-characterized complication in the broader Lyme literature.
"Despite the recognition of this complication of Lyme disease in the care of patients with PTLD, there has been a scarcity of research in this field and dysautonomia has not yet been established as a complication of Lyme disease in the medical literature." (abstract, background, passage verified)pubmedfull study (doi)
"The patients with Lyme disease showed distinct autonomic patterns, including a higher prevalence of orthostatic hypotension (53.4%) and changes in heart rate variability during the Head-Up Tilt Test suggestive of adrenergic failure." (abstract, results, passage verified)pubmedfull study (doi)
"On the 10-minute active stand test, 9 of the 210 (4.29%) patients with PTLD had orthostatic tachycardia. Although the prevalence of orthostatic tachycardia in patients was not significantly different from that of healthy controls, those with orthostatic tachycardia were more likely to be earlier in their disease course" (abstract, results, passage verified)pubmedfull study (doi)
"And the Horowitz MSIDS questionnaire, which is on my website, cangetbetter.com, if you take this questionnaire, it will give you a probability of tick-borne, but also you bring it to your doctor. There's 38 items on there... The beauty of the questionnaire is we validated it in 1,600 people." (said at 0:54:56)
A 2017 validation study by Horowitz and Freeman published in the International Journal of General Medicine evaluated the construct, convergent, and discriminant validity of the Horowitz Multiple Systemic Infectious Disease Syndrome Questionnaire (HMQ). The publication reported empirical evaluation across cohorts totaling over 1,500–1,600 participants (including Study 1 with 537 patients and Study 2 with 999 participants, alongside a third comparison cohort), finding acceptable internal reliability and ability to distinguish self-reported or confirmed Lyme disease patients from healthy controls.
"Three studies evaluated such a screening tool, namely the Horowitz Multiple Systemic Infectious Disease Syndrome (MSIDS) Questionnaire. The purpose was to see if the questionnaire could accurately distinguish between Lyme patients and healthy individuals. Study 1 examined the construct validity of the scale examining its factor structure and reliability of the questionnaire among 537 individuals being treated for Lyme disease. Study 2 involved an online sample of 999 participants, who self-identified as either healthy (N=217) or suffering from Lyme now (N=782) who completed the Horowitz MSIDS Questionnaire (HMQ) along with an outdoor activity survey." (abstract, methods, passage verified)pubmedfull study (doi)
"Fibromyalgia. I didn't learn in medical school that mycotoxins are showing up in 70 to 80% of fibromyalgia patients." (said at 0:55:30)
No published studies show that 70% to 80% of general fibromyalgia patients test positive for mycotoxins. The figures cited likely derive from observational studies in patients with chronic fatigue syndrome (ME/CFS) who had documented histories of exposure to water-damaged buildings. In a 2013 study of 112 ME/CFS patients with mold exposure, 83% tested positive for ochratoxin A (and 93% for at least one mycotoxin) on commercial ELISA urine assays. A subsequent 2022 study in mold-exposed ME/CFS patients found mycotoxins in 92.4% of urine samples. These findings reflect highly selected, mold-exposed ME/CFS populations rather than representative fibromyalgia cohorts, and the diagnostic reliability of urinary ELISA mycotoxin assays remains controversial.
"Patients (n = 112) with a prior diagnosis of CFS were evaluated for mold exposure and the presence of mycotoxins in their urine... Urine specimens from 104 of 112 patients (93%) were positive for at least one mycotoxin (one in the equivocal range). Almost 30% of the cases had more than one mycotoxin present. OTA was the most prevalent mycotoxin detected (83%) with MT as the next most common (44%). Exposure histories indicated current and/or past exposure to WDB in over 90% of cases." (abstract, results)pubmedfull study (doi)
"In this prevalence study, we investigated the rates of Aspergillus-derived toxin levels, Aflatoxin (AF), Ochratoxin A (OTA), and Gliotoxin (GT), in the urinalysis of 236 ME/CFS patients with a history of chronic exposure to mold (i.e., from water-damaged buildings). Among ME/CFS patients reporting chronic exposure to mold, we found evidence of exposure in 92.4 percent of patients, with OTA being the most prevalent mycotoxin." (abstract, results, passage verified)pubmedfull study (doi)
"And the problem is that they're mitochondrial poisons and they're affecting your immune system and they cause fatigue, brain fog, pain, neuropathy." (said at 1:01:19)
No published record matching the claim that mycotoxins act as mitochondrial poisons, impair the immune system, and directly cause fatigue, brain fog, pain, and neuropathy in humans was located; this does not prove the claim false.
"And these are from Quest, like you can get a p-tau 181, p-tau 217, neurofilament light, and beta-amyloid 42/40 ratio from Quest Laboratories, and it is completely covered." (said at 1:01:37)
The statement bundles two distinct claims: commercial availability of specific blood biomarkers and universal insurance coverage. While Quest Diagnostics has developed and offers clinical assays for plasma amyloid-beta 42/40 ratio, phosphorylated tau (p-tau181, p-tau217), and neurofilament light (NfL) to aid in Alzheimer's disease evaluation, the assertion that these tests are 'completely covered' is overstated. Published reviews on the clinical implementation of Alzheimer's blood biomarkers highlight that routine clinical adoption, standardized reimbursement, and comprehensive insurance coverage remain major barriers, with patients frequently facing out-of-pocket costs.
"Aβ42/40 ratio was measured by LC-MS/MS for 250 specimens with associated amyloid PET imaging, diagnosis, and demographic data, and for 6,192 consecutive clinical specimens submitted for Aβ42/40 testing." (abstract, results, passage verified)pubmedfull study (doi)
"It covers recent advances in blood biomarkers, including amyloid beta (Aβ) peptides, tau protein, neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP). It also discusses their diagnostic and prognostic utility while addressing associated challenges and limitations." (abstract, passage verified)pubmedfull study (doi)
"Despite these advancements, however, significant work is needed before AD BBMs can be implemented in widespread clinical practice. Cutpoints must be established, the influence of chronic conditions and medications on BBM levels must be better understood, and guidelines must be created for healthcare providers related to interpreting and communicating information obtained from AD BBMs." (abstract, passage verified)pubmedfull study (doi)
"VEGF we see with Long COVID, but we see it with Bartonella, you'll see with cancer." (said at 1:02:14)
Elevated vascular endothelial growth factor (VEGF/VEGFA) levels and signaling have been documented in Long COVID cohorts, Bartonella infections, and malignant cancers. Proteomic analyses of patients with post-acute sequelae of COVID-19 (Long COVID) demonstrate significant upregulation of circulating VEGFA compared to recovered controls. In Bartonella species infections (such as B. henselae and B. quintana), the bacteria stimulate host cells to secrete VEGF and express factors that activate the VEGF pathway, driving characteristic vasoproliferative lesions (such as bacillary angiomatosis). In oncology, tumor-derived VEGF overexpression is a well-established hallmark that mediates tumor angiogenesis.
"Remarkably, only B. quintana strain JK-31 induced secretion of vascular endothelial growth factor (VEGF) from THP-1 and HeLa 229 cells upon infection similar to the secretion induced by B. henselae Marseille" (abstract, results, passage verified)pubmedfull study (doi)
"Pathogenic bacteria of the genus Bartonella can induce vasoproliferative lesions during infection. The underlying mechanisms are unclear, but involve secretion of an unidentified mitogenic factor. Here, we use functional transposon-mutant screening in Bartonella henselae to identify such factor as a pro-angiogenic autotransporter, called BafA." (abstract, results, passage verified)pubmedfull study (doi)
"Findings revealed VEGFA overexpression in long COVID patients (effect size 0.322, SE = 0.098, p = 0.0013), along with sex-specific expression patterns and the influence of sex-hormonal status in females, with significant overexpression of circulating VEGFA levels specifically in postmenopausal women" (abstract, results, passage verified)pubmedfull study (doi)
"There are food mycotoxins, about 25% are probably coming from foods also." (said at 1:03:40)
No published record matching the claim that approximately 25 percent of mycotoxins detected in human testing originate from dietary food sources was located; this does not prove the claim false. In toxicology and public health biomonitoring, diet (e.g., consumption of contaminated grains, nuts, spices, and cereals) is widely recognized as the predominant route of human exposure to regulated mycotoxins such as deoxynivalenol, ochratoxin A, and aflatoxins, but no validated scientific ratio establishes a fixed 25% dietary contribution versus other routes.
"Mycotoxins are potent fungal toxins that frequently contaminate agricultural crops and foods. Mycotoxin exposure is frequently reported in humans, and children are known to be particularly at risk of exceeding safe levels of exposure. Urinary biomonitoring is used to assess overall dietary exposure to multiple mycotoxins." (abstract, results, passage verified)pubmedfull study (doi)
"60% of Americans have one chronic illness, 25% have two or more, 86% of our health care costs, and 70% is chronic disease." (said at 1:09:01)
The speaker's statement roughly reflects national surveillance data from the Centers for Disease Control and Prevention (CDC), but blends estimates from different definitions of chronic illness. Analyses of the National Health Interview Survey (NHIS) examining 10 major conditions (arthritis, cancer, COPD, coronary heart disease, asthma, diabetes, hepatitis, hypertension, stroke, and kidney disease) found that 51.1% to 51.8% of US adults had at least one condition and 26.4% to 27.2% (roughly 25%) had multiple chronic conditions (two or more). When broader definitions of chronic disease are used, the CDC frequently cites that 6 in 10 (60%) US adults have at least one chronic condition and 4 in 10 (40%) have two or more.
"More than half (51.8%) of adults had at least 1 of 10 selected diagnosed chronic conditions (arthritis, cancer, chronic obstructive pulmonary disease, coronary heart disease, current asthma, diabetes, hepatitis, hypertension, stroke, and weak or failing kidneys), and 27.2% of US adults had multiple chronic conditions." (abstract, results, passage verified)pubmedfull study (doi)
"According to the Centers for Disease Control and Prevention, six out of every ten adults in the United States have at least one chronic disease, and about four in ten have two or more chronic diseases" (abstract, passage verified)pubmedfull study (doi)
"In 2024, 51.1% of US adults had at least 1 of 10 selected diagnosed chronic conditions, and 26.4% had MCC." (abstract, results, passage verified)pubmedfull study (doi)
"86% of our health care costs, and 70% is chronic disease." (said at 1:09:06)
The claim is supported by national health surveillance and expenditure data. According to analysis published by the Centers for Disease Control and Prevention (CDC), chronic health conditions account for 86% of total healthcare spending in the United States, alongside being the leading causes of death and disability.
"Chronic conditions profoundly affect quality of life, are leading causes of death and disability, and account for 86% of total health care spending." (abstract, passage verified)pubmed
"It's in the Journal of Alzheimer's Disease Reports, April 2024. So anyone can read it. But what astonished me is this p-tau 217, which most neurologists consider to be the most sensitive and specific biomarker, I reversed it completely to normal by 63% in nine weeks with an oral antibiotic regimen." (said at 1:13:22)
No published record matching the reported April 2024 case report in the Journal of Alzheimer's Disease Reports describing a 63% normalization of the p-tau 217 biomarker in nine weeks following an oral antibiotic regimen was located; this does not prove the claim false.
"But here's the beauty is dapsone combination therapy, the number one effect it always had was improving people's memory statistically in these 375 patients." (said at 1:13:40)
No published record matching a study of 375 patients evaluating dapsone combination therapy with statistically improved memory as its primary effect was located; this does not prove the claim false. Published retrospective chart reviews and observational cohorts on dapsone combination therapy in chronic Lyme disease/post-treatment Lyme disease syndrome report cohorts of 200 patients (evaluating eight general symptom categories without isolating memory as a primary endpoint), 40 patients, and 25 patients, rather than 375 patients.
"A total of 200 adult patients recruited from a specialized Lyme disease medical practice had been ill for at least 1 year... DDS CT statistically improved the eight major Lyme symptoms." (abstract, results)pubmedfull study (doi)
"People, you know, don't realize like if you have cardiovascular risks and you're taking xylitol in your diet, which has now been linked, right, to strokes, right, that and now you have heat stress that you are more at risk for certain strokes than you might have been from the past." (said at 1:16:23)
A 2024 study published in the European Heart Journal (Witkowski et al.) found that elevated circulating levels of xylitol were significantly associated with an increased 3-year risk of incident major adverse cardiovascular events (MACE, which includes myocardial infarction and stroke) in an independent validation cohort of 2,149 patients (adjusted HR 1.57, 95% CI 1.12–2.21). Complementary mechanistic and interventional human studies demonstrated that dietary consumption of xylitol raised plasma levels, heightened platelet reactivity, and enhanced thrombosis potential.
"In initial untargeted metabolomics studies (discovery cohort), circulating levels of a polyol tentatively assigned as xylitol were associated with incident (3-year) major adverse cardiovascular event (MACE) risk. Subsequent stable isotope dilution LC-MS/MS analyses (validation cohort) specific for xylitol (and not its structural isomers) confirmed its association with incident MACE risk [third vs. first tertile adjusted hazard ratio (95% confidence interval), 1.57 (1.12-2.21), P < .01]. Complementary mechanistic studies showed xylitol-enhanced multiple indices of platelet reactivity and in vivo thrombosis formation at levels observed in fasting plasma." (abstract, results, passage verified)pubmedfull study (doi)